BACKGROUND: Readmissions following transcatheter aortic valve replacement (TAVR) are common but detailed analysis of cardiac and non-cardiac inpatient readmissions beyond thirty days to different levels of care are limited. METHODS: Our study population was 1,037 consecutive patients who underwent TAVR between 2011-2017 within a multi-hospital quaternary health system. A retrospective chart review was performed and readmissions were adjudicated and classified based on primary readmission diagnosis (cardiac versus noncardiac) and level of care [intensive care unit (ICU) admission vs. non-ICU admission]. Incidence, causes, and outcomes of readmissions to up to three years post procedure were evaluated. RESULTS: Of the 1,017 patients who survived their index hospitalization, there were readmissions due to noncardiac causes in 350 (34.4%) and cardiac causes in 208 (20.5%) during a mean 1.96 years of follow-up. The most common non-cardiac causes of readmission were sepsis/infection (14.3%), gastrointestinal (8.3%), and respiratory (4.8%), whereas heart failure (14.0%) and arrhythmias (4.6%) were the most common cardiac causes of readmission. A total of 191 (18.8%) patients were readmitted to the ICU and 372 patients (36.6%) were non-ICU readmissions. The risk of a noncardiac readmission was highest in the period immediately following TAVR (~4.5% per month) with an early high hazard phase that gradually declined over months. However, the risk of cardiac readmission remained stable at ~1% per month throughout. TAVR patients that were readmitted for any cause had markedly increased mortality; this was especially true for patients readmitted to an ICU. CONCLUSIONS: In TAVR patients who survived their index hospitalization, non-cardiac readmissions were more prevalent than cardiac. The risk of readmission and subsequent mortality was highest immediately post-procedure and declined thereafter. Readmission to ICU portends the highest risk of subsequent death in this cohort. Patient baseline co-morbidities are an important consideration for TAVR patients and play a significant role in readmissions and outcomes. 2021 Cardiovascular Diagnosis and Therapy. All rights reserved.
BACKGROUND: Readmissions following transcatheter aortic valve replacement (TAVR) are common but detailed analysis of cardiac and non-cardiac inpatient readmissions beyond thirty days to different levels of care are limited. METHODS: Our study population was 1,037 consecutive patients who underwent TAVR between 2011-2017 within a multi-hospital quaternary health system. A retrospective chart review was performed and readmissions were adjudicated and classified based on primary readmission diagnosis (cardiac versus noncardiac) and level of care [intensive care unit (ICU) admission vs. non-ICU admission]. Incidence, causes, and outcomes of readmissions to up to three years post procedure were evaluated. RESULTS: Of the 1,017 patients who survived their index hospitalization, there were readmissions due to noncardiac causes in 350 (34.4%) and cardiac causes in 208 (20.5%) during a mean 1.96 years of follow-up. The most common non-cardiac causes of readmission were sepsis/infection (14.3%), gastrointestinal (8.3%), and respiratory (4.8%), whereas heart failure (14.0%) and arrhythmias (4.6%) were the most common cardiac causes of readmission. A total of 191 (18.8%) patients were readmitted to the ICU and 372 patients (36.6%) were non-ICU readmissions. The risk of a noncardiac readmission was highest in the period immediately following TAVR (~4.5% per month) with an early high hazard phase that gradually declined over months. However, the risk of cardiac readmission remained stable at ~1% per month throughout. TAVR patients that were readmitted for any cause had markedly increased mortality; this was especially true for patients readmitted to an ICU. CONCLUSIONS: In TAVR patients who survived their index hospitalization, non-cardiac readmissions were more prevalent than cardiac. The risk of readmission and subsequent mortality was highest immediately post-procedure and declined thereafter. Readmission to ICU portends the highest risk of subsequent death in this cohort. Patient baseline co-morbidities are an important consideration for TAVR patients and play a significant role in readmissions and outcomes. 2021 Cardiovascular Diagnosis and Therapy. All rights reserved.
Authors: D Craig Miller; Eugene H Blackstone; Michael J Mack; Lars G Svensson; Susheel K Kodali; Samir Kapadia; Jeevanantham Rajeswaran; William N Anderson; Jeffrey W Moses; E Murat Tuzcu; John G Webb; Martin B Leon; Craig R Smith Journal: J Thorac Cardiovasc Surg Date: 2012-04 Impact factor: 5.209
Authors: Abhijeet Dhoble; Viraj Bhise; Moises I Nevah; Prakash Balan; Tom C Nguyen; Anthony L Estrera; Richard W Smalling Journal: Catheter Cardiovasc Interv Date: 2017-08-28 Impact factor: 2.692
Authors: David R Holmes; J Matthew Brennan; John S Rumsfeld; David Dai; Sean M O'Brien; Sreekanth Vemulapalli; Fred H Edwards; John Carroll; David Shahian; Fred Grover; E Murat Tuzcu; Eric D Peterson; Ralph G Brindis; Michael J Mack Journal: JAMA Date: 2015-03-10 Impact factor: 56.272
Authors: Steven A Frost; Patricia M Davidson; Evan Alexandrou; Leanne Hunt; Yenna Salamonson; Victor Tam; Michael Ja Parr; Anders Aneman; Ken M Hillman Journal: Crit Care Resusc Date: 2010-09 Impact factor: 2.159
Authors: Juan A Crestanello; Jeffrey J Popma; David H Adams; G Michael Deeb; Mubashir Mumtaz; Barry George; Jian Huang; Michael J Reardon Journal: JACC Cardiovasc Interv Date: 2017-11-01 Impact factor: 11.195
Authors: Frederick L Grover; Sreekanth Vemulapalli; John D Carroll; Fred H Edwards; Michael J Mack; Vinod H Thourani; Ralph G Brindis; David M Shahian; Carlos E Ruiz; Jeffrey P Jacobs; George Hanzel; Joseph E Bavaria; E Murat Tuzcu; Eric D Peterson; Susan Fitzgerald; Matina Kourtis; Joan Michaels; Barbara Christensen; William F Seward; Kathleen Hewitt; David R Holmes Journal: J Am Coll Cardiol Date: 2016-12-09 Impact factor: 24.094
Authors: Martin B Leon; Craig R Smith; Michael J Mack; Raj R Makkar; Lars G Svensson; Susheel K Kodali; Vinod H Thourani; E Murat Tuzcu; D Craig Miller; Howard C Herrmann; Darshan Doshi; David J Cohen; Augusto D Pichard; Samir Kapadia; Todd Dewey; Vasilis Babaliaros; Wilson Y Szeto; Mathew R Williams; Dean Kereiakes; Alan Zajarias; Kevin L Greason; Brian K Whisenant; Robert W Hodson; Jeffrey W Moses; Alfredo Trento; David L Brown; William F Fearon; Philippe Pibarot; Rebecca T Hahn; Wael A Jaber; William N Anderson; Maria C Alu; John G Webb Journal: N Engl J Med Date: 2016-04-02 Impact factor: 91.245
Authors: Anna Franzone; Thomas Pilgrim; Nicolas Arnold; Dik Heg; Bettina Langhammer; Raffaele Piccolo; Eva Roost; Fabien Praz; Lorenz Räber; Marco Valgimigli; Peter Wenaweser; Peter Jüni; Thierry Carrel; Stephan Windecker; Stefan Stortecky Journal: Eur Heart J Date: 2017-07-21 Impact factor: 29.983